At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 85 enrolled
Drug / intervention
Adalimumab every other week +1 moredrug
Likely dose
Adalimumab every other week 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Study to Evaluate the Efficacy and Safety of Adalimumab in Patients With Plaque Psoriasis Who Showed an Unsatisfactory Response to Etanercept
In Brief
A Phase 3 clinical trial evaluating Adalimumab every other week and Adalimumab Every Week for Plaque Psoriasis. Completed, enrolled 85 participants across 12 sites.
Detailed Summary
This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada
CollaboratorsAbbott
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
Primary CompletionSep 2008
Study CompletionDec 2008
First PostedJun 2009
TodayJul 2026
First PostedJun 24, 2009
Enrollment StartMar 1, 2007
Primary CompletionSep 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.0 years ago
Interventions
Adalimumab every other weekdrug
Adalimumab 40mg injection every other week for 24 weeks
Adalimumab Every Weekdrug
Adalimumab 40mg injection every week for the last 12 weeks of study.